Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 20;146(6):438–449. doi: 10.1161/CIRCULATIONAHA.121.058910

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 1. — Absolute change in eGFR from baseline to 14, 60, and 120 days in each treatment arm and change in eGFR with placebo and dapagliflozin according to baseline eGFR category (from top to bottom: ≥75, <75–≥60-, <60–≥45, <45 mL·min⁻¹·1.73 m⁻²). A, Violin plot illustrating the change in estimated glomerular filtration rate (eGFR) from baseline. Rectangle in the middle of the violin shows the median and interquartile range. Lines show the smoothed probability density at different values; therefore, the width of the violin corresponds to the distribution of the data. B, Change in eGFR over time in each treatment arm and each baseline eGFR category from a repeated-measures mixed-effect model. Dapa indicates dapagliflozin.